GEVI Form 4: $400,000 Series C buy, $6 warrant for 44,445
Rhea-AI Filing Summary
General Enterprise Ventures (GEVI) — insider Form 4 activity: A reporting person identified as a 10% owner reported multiple transactions. On 09/03/2025, 650,000 shares of Series C Convertible Preferred Stock were converted into 2,166,667 shares of Common Stock, bringing Common Stock beneficial ownership to 2,416,667 shares (direct). On 09/30/2025, the holder purchased 26,667 Series C shares for $400,000 at $15.00 per share and received a warrant to purchase 44,445 Common Stock at an exercise price of $6 per share, expiring 09/30/2030. The Series C is convertible into 3.3333 Common shares per preferred share and has no expiration. An adjustment on 06/30/2025 added 69,007 Series C to offset dilution. Figures reflect GEVI’s 1‑for‑6 reverse split effective 08/28/2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series C Convertible Preferred Stock | 26,667 | $0.00 | $0.00 |
| Purchase | Warrant | 44,445 | $0.00 | $0.00 |
| Conversion | Series C Converticle Preferred Stock | 650,000 | $0.00 | $0.00 |
| Conversion | Common Stock | 2,166,667 | $0.00 | $0.00 |
| Other | Series C Convertible Preferred Stock | 69,007 | $0.00 | $0.00 |
Footnotes (5)
- F1. Each share of Series C Convertible Preferred Stock is convertible at any time at the option of the holder into 3.3333 shares of Common Stock. The Series C Convertible Preferred Stock has no expiration date.
- F2. Represents shares of Series C Convertible Preferred Stock issued to the Reporting Person pursuant to an adjustment under the March 2025 Share Purchase Agreement to offset dilution from subsequent equity issuances.
- F3. On September 30, 2025, the Reporting Person entered into a securities purchase agreement (the "Securities Purchase Agreement") with the Issuer, pursuant to which the Reporting Person purchased 26,667 shares of Series C Convertible Preferred Stock (the "Series C Shares") for an aggregate purchase price of $400,000 ($15.00 per Series C Share).
- F4. The Warrant is exercisable at any time by the Reporting Person prior to its expiration.
- F5. In connection with the execution of the Securities Purchase Agreement, the Reporting Person also executed a common stock purchase warrant agreement (the "Warrant Agreement"), pursuant to which the Issuer issued a warrant to the Reporting Person. The Warrant Agreement entitles the Reporting Person to purchase from the Issuer up to 50% of the number of shares of Common Stock issuable upon full conversion of all the Series C Shares purchased by the Reporting Person, subject to the terms and conditions of the Warrant Agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.